Abstract

T-DM1 is the standard of care for adjuvant treatment of patients (pts) with HER2-positive early breast cancer (eBC) who have invasive residual disease after pre-operative treatment with taxane and HER2-targeted therapy. However a high unmet need remains in some higher risk subgroups (eg, inoperable or lymph node-positive, hormone receptor-negative disease) who have 3-year invasive disease-free survival (IDFS) rates of 76%. Exploratory analyses suggest that addition of the PD-L1 inhibitor atezolizumab to T-DM1 results in longer progression-free survival compared to T-DM1 alone in pts with previously treated PD-L1-positive metastatic BC.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.